Personalized treatments create paradigm shift in AML
Acute myeloid leukemia (AML), the most common form of leukemia in adults, has historically been associated with poor five-year overall survival rates. AML is witnessing a paradigm shift from chemotherapy-based treatment toward increasingly targeted and personalized combination therapies. With the uptake of new therapies and combinations, we expect the AML market to grow substantially over the forecast period. Additionally, several drug developers are engaged in the race to launch new therapies in the AML market. The late-phase pipeline is active and spans several drug classes, including reformulations of existing drugs, novel chemotherapies, novel antibody technologies, and small molecules.